Search
Lutein
go.drugbank.com/drugs/DB00137ApprovedNutraceuticalIn green plants, xanthophylls act to modulate light energy and serve as non-photochemical quenching agents to deal with triplet chlorophyll (an excited form of chlorophyll), which is overproduced at very
Mixtures: RE FAC-xPeanut oil
go.drugbank.com/drugs/DB13964ApprovedWithdrawnThe peanut oil represents about 45-52% of the kernel content and it is mainly formed from monounsaturated fat from which the major component is [DB04224]. … The kernels are consumed roasted but a large percentage is used for the production of vegetable oil.
Lutetium Lu-177 vipivotide tetraxetan
go.drugbank.com/drugs/DB16778ApprovedInvestigational[L41290] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended lutetium Lu-177 vipivotide tetraxetan be granted marketing authorization for the treatment of prostate … It consists of a radionuclide, [lutetium Lu-177], linked to a moiety that binds to PSMA, a transmembrane protein that is expressed in prostate cancer.
Indomethacin
go.drugbank.com/drugs/DB00328ApprovedInvestigational[A177871] Since then, indometacin has been extensively studied in clinical trials as one of the most potent NSAIDs in blocking prostaglandin synthesis and was among the first NSAIDs to be used in the symptomatic … [A177871] The pharmacological effect of indometacin is not fully understood, however, it is thought to be mediated through potent and nonselective inhibition of the enzyme cyclooxygenase (COX), which is
Lurasidone
go.drugbank.com/drugs/DB08815ApprovedInvestigationalIt was approved by the U.S. … Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeGefapixant
go.drugbank.com/drugs/DB15097Approved[L48596,L48591] It is the first therapy to be approved for the treatment of RCC or UCC in the EU.[L48601] … [L48596] Gefapixant is a novel antagonist of the P2X3 receptor that works to reduce the cough reflex in patients with chronic cough.
Mitapivat
go.drugbank.com/drugs/DB16236ApprovedInvestigationalIt works to increase the activity of erythrocyte pyruvate kinase, a key enzyme involved in the survival of red blood cells. … Defects in the pyruvate kinase enzyme in various red blood cells disorders lead to the lack of energy production for red blood cells, leading to lifelong premature destruction of red blood cells or chronic
Apixaban
go.drugbank.com/drugs/DB06605ApprovedInvestigationalIt is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012[L6043]. … Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic
Prucalopride
go.drugbank.com/drugs/DB06480ApprovedInvestigational[A37348] The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. … Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties.
Products: RESOLOR ® TABLETAS RECUBIERTAS DE 2 MG, RESOLOR ® TABLETAS RECUBIERTAS DE 1 MGLenacapavir
go.drugbank.com/drugs/DB15673ApprovedInvestigationalHIV/AIDS remains an area of concern despite the introduction of numerous successful therapies, mainly due to the emergence of multidrug resistance and patient difficulty in adhering to treatment regimens … [L42995] On December 22, 2022, it was also approved by the FDA.[L44473]